|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
KR940703846A
(ko)
|
1991-12-24 |
1994-12-12 |
비. 린네 파샬 |
갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
|
|
US6169169B1
(en)
|
1994-05-19 |
2001-01-02 |
Dako A/S |
PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
|
|
WO2006007712A1
(en)
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
|
CA2895155C
(en)
|
2012-12-17 |
2021-07-06 |
President And Fellows Of Harvard College |
Rna-guided human genome engineering
|
|
EP3608308B1
(en)
|
2013-03-08 |
2021-07-21 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
AU2014227653B2
(en)
|
2013-03-15 |
2017-04-20 |
The General Hospital Corporation |
Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
ES2895651T3
(es)
|
2013-12-19 |
2022-02-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para la administración de agentes activos
|
|
EP3169309B1
(en)
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
ES2964690T3
(es)
|
2015-09-21 |
2024-04-09 |
Trilink Biotechnologies Llc |
Método para sintetizar ARN con caperuza 5'
|
|
TWI773666B
(zh)
|
2016-03-30 |
2022-08-11 |
美商英特利亞醫療公司 |
Crispr/cas 組分之脂質奈米粒子調配物
|
|
WO2018067447A1
(en)
|
2016-10-03 |
2018-04-12 |
Itellia Therapeutics, Inc. |
Improved methods for identifying double strand break sites
|
|
CA3057192A1
(en)
*
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
PT3688162T
(pt)
|
2017-09-29 |
2024-04-23 |
Intellia Therapeutics Inc |
Formulações
|
|
AR113154A1
(es)
|
2017-09-29 |
2020-01-29 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para edición del genoma
|
|
AU2018364993B2
(en)
|
2017-11-10 |
2022-10-06 |
University Of Massachusetts |
Targeted CRISPR delivery platforms
|
|
EP3850088A4
(en)
*
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
WO2020072605A1
(en)
|
2018-10-02 |
2020-04-09 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids
|
|
BR112021007123A2
(pt)
|
2018-10-15 |
2021-08-10 |
University Of Massachusetts |
edição de base de dna programável pelas proteínas de fusão nme2cas9-desaminase
|
|
IL314386A
(en)
|
2018-12-05 |
2024-09-01 |
Intellia Therapeutics Inc |
amine modified lipids
|
|
BR112021019224A2
(pt)
|
2019-03-28 |
2021-11-30 |
Intellia Therapeutics Inc |
Polinucleotídeos, composições e métodos para expressão de polipeptídeo
|
|
WO2020219876A1
(en)
|
2019-04-25 |
2020-10-29 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
AU2020293211B2
(en)
*
|
2019-06-11 |
2026-03-05 |
Pairwise Plants Services, Inc. |
Methods of producing plants with altered fruit development and plants derived therefrom
|
|
CN114616002A
(zh)
*
|
2019-09-13 |
2022-06-10 |
瑞泽恩制药公司 |
使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控
|
|
CR20230305A
(es)
*
|
2020-12-11 |
2023-11-10 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación
|